Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Business Overview and Strategy
JAZZ logo

Jazz Pharma's Xywav Sales Surge 16% Amid Pipeline Wins

JAZZ10-KFiling Date: 4/25/2025
Jazz Pharmaceuticals plc
Description

What this story covers

Jazz Pharmaceuticals reports strong 2024 growth with Xywav at $1.47B (up 16%) and Epidiolex at $972M (up 15%), driven by commercial expansion and R&D milestones like Ziihera approval. Compensation aligns with performance; governance emphasizes independence. Risks include pipeline setbacks and competition.

Story snapshot

CompanyJazz Pharmaceuticals plc
TickerJAZZ
VariantStandard detailed
Duration13:12
Filing type10-K
PeriodAnnual 2024
IndustryHealthcare & Pharmaceuticals
Accession0001232524-25-000014

Full Story Script

Content not available for this story.

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in